Literature DB >> 18292948

Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors.

Naoya Tatsumi1, Yusuke Oji, Naoko Tsuji, Asako Tsuda, Mari Higashio, Sayaka Aoyagi, Ikuyo Fukuda, Ken Ito, Junya Nakamura, Satoshi Takashima, Yayoi Kitamura, Saori Miyai, Tanyarat Jomgeow, Zheyu Li, Toshiaki Shirakata, Sumiyuki Nishida, Akihiro Tsuboi, Yoshihiro Oka, Haruo Sugiyama.   

Abstract

Wilms' tumor gene WT1 is overexpressed in leukemia and various types of solid tumors and plays an important role in leukemogenesis and tumorigenesis. We tested apoptosis-inducing ability of short hairpin RNAs targeting exon 5 (shWTE5), exon10 (shWTE10) and 3'UTR (shWT3U) of the WT1 gene. Among the three WT1-shRNAs, since shWTE5 most effectively induced apoptosis, its ability as an apoptosis-inducing agent was intensively examined. shWTE5 induced mitochondrial damage and resultant apoptosis in five WT1-expressing solid cancer cells originated from gastric (AZ-521), lung (LU99B), ovarian (TYKnuCPr) cancers, fibrosarcoma (HT-1080) and glioblastoma (A172). Moreover, shWTE5 significantly enhanced apoptosis induced by chemotherapeutic agents, doxorubicin (DOX) and etoposide (ETP), or by death ligand TRAIL in all of the four solid tumor cells examined (HT-1080, LU99B, TYK and A172). Transduction of one each of WT1 isoforms with exon 5 [17AA(+)KTS(+) and 17AA(+)KTS(-)] prevented mitochondrial damage induced by ETP or TRAIL and inhibited apoptosis. These results showed that shWTE5 induced apoptosis through the suppression of the WT1 isoform with exon 5. Furthermore, shWTE5 increased expression of proapoptotic Bak and Bax proteins and decreased antiapoptotic Bcl-xL and Bcl-2 proteins in WT1-expressing HT-1080 cells, indicating that WT1 isoforms with exon 5 might play an antiapoptotic role through regulation of Bcl-2 family genes in solid tumor cells. The results presented here demonstrated that WT1-shRNA targeting exon 5 should serve as a potent anti-cancer agent for various types of solid tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18292948

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  30 in total

Review 1.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

2.  Antitumor effects of minodronate, a third-generation nitrogen-containing bisphosphonate, in synergy with γδT cells in human glioblastoma in vitro and in vivo.

Authors:  Tsutomu Nakazawa; Mitsutoshi Nakamura; Ryosuke Matsuda; Fumihiko Nishimura; Young Soo Park; Yasushi Motoyama; Yasuo Hironaka; Ichiro Nakagawa; Hiroshi Yokota; Shuichi Yamada; Kentaro Tamura; Yasuhiro Takeshima; Kouji Omoto; Yoshitaka Tanaka; Yukiteru Ouji; Masahide Yoshikawa; Takahiro Tsujimura; Hiroyuki Nakase
Journal:  J Neurooncol       Date:  2016-07-08       Impact factor: 4.130

3.  G-quadruplex forming region within WT1 promoter is selectively targeted by daunorubicin and mitoxantrone: A possible mechanism for anti-leukemic effect of drugs.

Authors:  Saeedeh Ghazaey Zidanloo; Abasalt Hosseinzadeh Colagar; Hossein Ayatollahi; Zahra Bagheryan
Journal:  J Biosci       Date:  2019-03       Impact factor: 1.826

4.  Wilms' tumor 1 gene modulates Fas-related death signals and anti-apoptotic functions in hepatocellular carcinoma.

Authors:  Kazuhiro Uesugi; Yoichi Hiasa; Yoshio Tokumoto; Toshie Mashiba; Yohei Koizumi; Masashi Hirooka; Masanori Abe; Bunzo Matsuura; Morikazu Onji
Journal:  J Gastroenterol       Date:  2012-11-10       Impact factor: 7.527

5.  Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.

Authors:  Ekaterina Doubrovina; Taissia Carpenter; Dmitry Pankov; Annamalai Selvakumar; Aisha Hasan; Richard J O'Reilly
Journal:  Blood       Date:  2012-05-23       Impact factor: 22.113

6.  Effects of WT1 gene downregulation on apoptosis in porcine fetal fibroblasts.

Authors:  Peipei An; Yu Ding; Aibing Wang; Wentao Tan; Fei Gao; Anran Fan; Bo Tang; Xueming Zhang; Ziyi Li
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-03-21       Impact factor: 2.416

7.  WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells.

Authors:  Pablo Zapata-Benavides; Edgar Manilla-Muñoz; Diana E Zamora-Avila; Santiago Saavedra-Alonso; Moisés A Franco-Molina; Laura M Trejo-Avila; Guillermo Davalos-Aranda; Cristina Rodríguez-Padilla
Journal:  Oncol Lett       Date:  2012-01-19       Impact factor: 2.967

8.  HtrA2, taming the oncogenic activities of WT1.

Authors:  Jörg Hartkamp; Stefan G E Roberts
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

9.  Differential sensitization of two human colon cancer cell lines to the antitumor effects of irinotecan combined with 5-aza-2'-deoxycytidine.

Authors:  Shuko Hakata; Jun Terashima; Yu Shimoyama; Kouji Okada; Shiho Fujioka; Erika Ito; Wataru Habano; Shogo Ozawa
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

10.  The Wilms' tumor suppressor protein WT1 is processed by the serine protease HtrA2/Omi.

Authors:  Jörg Hartkamp; Brian Carpenter; Stefan G E Roberts
Journal:  Mol Cell       Date:  2010-01-29       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.